We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

By LabMedica International staff writers
Posted on 19 Apr 2024
Print article
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample. However, tumors are heterogeneous, containing multiple subpopulations of cells, or clones, each potentially responding differently to treatments. This variability may explain why some patients either fail to respond to certain treatments or develop resistance. Single-cell RNA sequencing offers higher-resolution data than bulk sequencing, capturing data at the single-cell level. This approach to identify and target individual clones may lead to more lasting drug responses, although, single-cell gene expression data are more expensive to generate and less accessible in clinical environments.

In a proof-of-concept study, researchers at the National Institutes of Health (NIH, Bethesda, MD, US) have developed an artificial intelligence (AI) tool that leverages data from individual tumor cells to predict how well a person's cancer might respond to a specific drug. This study demonstrates the potential of single-cell RNA sequencing in helping oncologists match effective therapies to their patients. In the new study, the team employed a machine learning technique known as transfer learning to train an AI model using common bulk RNA sequencing data, after which they used single-cell RNA sequencing data to fine-tune the model. This method was applied to existing cell-line data from comprehensive drug response trials, resulting in AI models for 44 FDA-approved cancer drugs that could predict cellular reactions to both individual and drug combinations.

Further testing involved data from 41 multiple myeloma patients treated with four drugs and 33 breast cancer patients treated with two drugs. The findings revealed that resistance in any single-cell clone could render the treatment ineffective, even if other clones were responsive. The model also successfully predicted resistance development in data from 24 patients with non-small cell lung cancer undergoing targeted therapies. The researchers noted that the accuracy of this approach can improve as single-cell RNA sequencing becomes more widely available. To facilitate broader use, the researchers have created a research website and a guide, dubbed Personalized Single-Cell Expression-based Planning for Treatments In Oncology (PERCEPTION), for applying the AI model to new datasets.

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.